IL-17 and IL-23 Pathways in Psoriasis Treatment

This chapter explores the critical roles of IL-17 and IL-23 signaling pathways in psoriasis, detailing how they contribute to immune system overactivity and associated complications. The effectiveness of various biologic therapies targeting these pathways is examined, showcasing advancements in treatment outcomes for skin and joint manifestations of the disease. It further discusses the safety considerations of these treatments, including the new bimikizumab medication that targets both IL-17A and IL-17F.